Faster targeted therapy leads to reduced costs and improved outcomes
The T2Candida® Panel is the first and only FDA-cleared diagnostic test for the detection of sepsis-causing fungal pathogens, direct from whole blood. Species identification is provided within 3 to 5 hours of the first blood draw and independent of a positive blood culture, often before the second dose of antimicrobials is administered.
T2Candida is most clinically impactful for patients in any of these conditions1:
Admitted to the ICU
Have febrile neutropenia
Have septic shock
Have an LVAD and evidence of active infection
In ICU at high risk for candidemia
Better patient outcomes: Candida infections have an overall mortality rate of 40%, but if patients receive targeted treatment within 12 hours, the mortality rate can be reduced to 11%.2,3 T2Candida provides a clear and compelling solution, by providing results in just hours without waiting for slow-growing fungal infections, which are often mistaken as bacterial infections, to reach positivity. One model estimates that early diagnosis with T2Candida may prevent an estimated 60% of Candida-related deaths.4
Unprecedented speed and accuracy: The T2Candida Panel pivotal clinical trial demonstrated results in 3 to 5 hours5, while other methods require a positive blood culture before the identification of Candida species. The T2Candida panel can detect species at concentrations of just 1-3 CFU/mL 5, a considerable improvement over blood cultures that have a low sensitivity of only 60% for Candida species and are susceptible to interference from antimicrobials6. Blood cultures have a median time to positivity of 2-3 days and negative results determined after 5 days of inactive growth. T2Candida empowers clinicians to make important clinical decisions sooner.
Faster targeted therapy: Studies have shown that the time to targeted therapy greatly impacts patient outcomes and reduces mortality rates, with corresponding reductions in healthcare costs from shorter length of stay, and a reduction in the overuse of antifungals. It’s estimated that the T2Candida Panel can save roughly $27,000 per patient due to faster results and subsequent targeted therapy.4 See how Henry Ford in Michigan and Lee Health in Florida have demonstrated faster targeted therapy for patients in clinical care for more than 24 hours.8,9
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
New @OFIDJournal article on Sepsis and COVID-19 provides a “call to action” to change the dynamic of dealing with sepsis. Authors advocate for widespread adoption and implementation of rapid diagnostics, including culture-independent diagnostics.